| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.039 | 0.8 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |